SCHEMBL22600583

SCHEMBL22600583

Fc1c(Br)c(I)cc2c(Cl)nc(C3CCOC3)nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24378838 0.93 GSK3A (0.31)
SCHEMBL22600701 0.83 NPC1 (0.32)
SCHEMBL22600553 0.79 HRH4 (0.35)
SCHEMBL22600706 0.77 ALDH1A1 (0.33)
SCHEMBL24378845 0.77 HRH4 (0.30)
SCHEMBL22600592 0.77 PARP14 (0.38)
SCHEMBL29592633 0.72
SCHEMBL26623643 0.72
SCHEMBL21379233 0.72
SCHEMBL22600573 0.72 PARP14 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3967695-B1 1-(7-(QUINAZOLIN-4-YL)-2,7-DIAZASPIRO[3.5]NONAN-2-YL)PROP-2-EN-1-ONE DERIVATIVES AS KRAS INHIBITORS FOR THE TREATMENT OF CANCER BETTA PHARMACEUTICALS CO LTD (CN) 2024-01-17 EP disclosed
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2023-07-13 US disclosed
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2023-07-13 US disclosed
WO-2022083616-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF 贝达药业股份有限公司 2022-04-28 WO disclosed
WO-2020216190-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF 贝达药业股份有限公司 2020-10-29 WO disclosed